denosumab
Brand names: Prolia, Xgeva
Stoboclo is a medicine that helps to treat osteoporosis and increase bone mass. It works by blocking a protein that breaks down bone.
Drug Pricing (NADAC)
Brand Price
$1723.69/unit
Generic Available
No
Pricing data from NADAC (CMS), effective November 20, 2024. Compare all drug costs →
What it does
Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures.
Common side effects
Back pain, Pain in your arms or legs, Muscle and bone pain
Key warnings
Stoboclo can cause very low calcium levels in people with serious kidney disease, especially those on dialysis.
How It Works
Stoboclo blocks a protein called RANKL. RANKL tells your body to break down bone. By blocking RANKL, Stoboclo slows down bone loss and helps to increase bone mass.
How to Take It
Stoboclo is given as a shot under the skin by a healthcare provider. You will get a 60 mg shot once every 6 months. The shot can be given in your upper arm, upper thigh, or abdomen. You also need to take 1000 mg of calcium and at least 400 IU of vitamin D every day.
Pregnancy & Breastfeeding
Stoboclo can harm your unborn baby. You should not take Stoboclo if you are pregnant. If you are able to get pregnant, you should use birth control while taking Stoboclo and for at least 5 months after your last dose.
Missed Dose
If you miss a dose of Stoboclo, get the shot as soon as you can. Then, schedule your next shot 6 months from the date of that shot.
Storage
Store Stoboclo in the refrigerator, between 36°F and 46°F (2°C to 8°C), in its original carton to protect it from light. Do not freeze it.
Side Effects (from patient reports)
Based on 111,821 FDA adverse event reports.
FDA Adverse Event Report Analysis
Detailed analysis of 196,342 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2008–2025.
Total Reports
196,342
Death-Related Reports
25,105
Hospitalization Reports
30,164
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | OFF LABEL USE | 36,484 |
| 2 | DEATH | 19,930 |
| 3 | ARTHRALGIA | 8,682 |
| 4 | OSTEONECROSIS OF JAW | 8,425 |
| 5 | FATIGUE | 7,481 |
| 6 | PAIN IN EXTREMITY | 6,893 |
| 7 | PAIN | 6,774 |
| 8 | BACK PAIN | 6,757 |
| 9 | NAUSEA | 5,301 |
| 10 | DIARRHOEA | 5,093 |
| 11 | FALL | 4,973 |
| 12 | RASH | 4,215 |
| 13 | MYALGIA | 4,163 |
| 14 | BONE PAIN | 3,978 |
| 15 | ASTHENIA | 3,959 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Stoboclo can cause very low calcium levels in people with serious kidney disease, especially those on dialysis. This can lead to hospitalization, life-threatening problems, and even death. If you have kidney problems, your doctor should check you for mineral and bone disorders before you start Stoboclo. You should be watched closely by a doctor who knows how to treat these problems.
Common Questions
What if I have kidney problems?
Can I take Stoboclo if I'm pregnant?
How often do I get the Stoboclo shot?
What else should I take with Stoboclo?
What are the most common side effects?
What if I have low calcium levels?
Can Stoboclo cause problems with my jaw?
What happens if I stop taking Stoboclo?
Can I give myself the Stoboclo shot?
What should I do if I have signs of an infection?
What are the common side effects of denosumab?
What drug class is denosumab?
Is denosumab safe during pregnancy?
Related Medications in RANK Ligand Inhibitor
Other drugs grouped near denosumab — same-class peers and common alternatives.
abaloparatide
Tymlos
Tymlos is a medicine to treat osteoporosis.
Compare with denosumab →
alendronate
Fosamax
Binosto is a medicine that helps make your bones stronger.
Compare with denosumab →
calcitonin
Miacalcin, Fortical
Calcitonin is a medicine that helps manage calcium levels in your body.
Compare with denosumab →
ibandronate
Boniva
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause.
Compare with denosumab →
risedronate
Actonel
Risedronate sodium delayed-release tablets help treat osteoporosis after menopause.
Compare with denosumab →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Related Health & Safety Data
🩺 Find a Doctor
Search prescribers for RANK Ligand Inhibitor
🏨 Hospital Quality
CMS hospital ratings, safety scores & patient outcomes
💊 Supplement Data
NIH DSLD — check supplement ingredients & label claims
🍽️ Food Safety Alerts
FDA recalls, inspections & outbreak investigations
⚠️ Product Recalls
FDA, CPSC & NHTSA recall search
💉 Procedure Costs
Medicare procedure pricing for 9,297 procedures
Save on denosumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for denosumab
The FDA label for denosumab (sold under brand names such as Prolia, Xgeva) classifies it as a prescription-only medication in the RANK Ligand Inhibitor class. Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures. Official labeling lists 7 commonly reported side effects, including Back pain, Pain in your arms or legs, Muscle and bone pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 111,821 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: October 22, 2025
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- FDA Orange Book — approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed — NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) — post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm — standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files — federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database — current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages